Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.

Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG.

J Clin Oncol. 2019 Jun 19:JCO1900107. doi: 10.1200/JCO.19.00107. [Epub ahead of print]

PMID:
31216227
2.

Targeting V-ATPase Isoform Restores Cisplatin Activity in Resistant Ovarian Cancer: Inhibition of Autophagy, Endosome Function, and ERK/MEK Pathway.

Kulshrestha A, Katara GK, Ibrahim SA, Riehl V, Sahoo M, Dolan J, Meinke KW, Pins MR, Beaman KD.

J Oncol. 2019 Apr 1;2019:2343876. doi: 10.1155/2019/2343876. eCollection 2019.

3.

Hepatoid Carcinoma of the Ovary: Clinical, Histopathologic, and Immunophenotypic Features.

Acosta AM, Pins MR.

Arch Pathol Lab Med. 2019 Jul;143(7):883-889. doi: 10.5858/arpa.2017-0485-RS. Epub 2019 Jan 10.

PMID:
30628840
4.
5.

The role of next-generation sequencing in the differential diagnosis of composite neoplasms.

Acosta AM, Al Rasheed MRH, Pins MR, Borgen KR, Panchal D, Rogozinska M, Wiley EL, Behm FG, Mohapatra G.

Hum Pathol. 2018 Nov;81:78-88. doi: 10.1016/j.humpath.2018.06.022. Epub 2018 Jun 26.

PMID:
29958927
6.

Sebaceous carcinoma of the breast in a patient with a pathogenic BRCA2 (886delGT) mutation - focus on histopathologic and immunohistochemical features.

Acosta AM, Al Rasheed MRH, Xu H, Salibay C, Pins MR.

APMIS. 2018 Apr;126(4):353-356. doi: 10.1111/apm.12826.

PMID:
29575201
7.

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.

Jilaveanu LB, Puligandla M, Weiss SA, Wang XV, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas NB, Kluger HM.

Clin Cancer Res. 2018 Jan 1;24(1):217-223. doi: 10.1158/1078-0432.CCR-17-1555. Epub 2017 Oct 24.

8.

A novel cytogenetic and molecular characterization of renal metanephric adenoma: Identification of partner genes involved in translocation t(9;15)(p24;q24).

Catic A, Kurtovic-Kozaric A, Johnson SH, Vasmatzis G, Pins MR, Kogan J.

Cancer Genet. 2017 Aug;214-215:9-15. doi: 10.1016/j.cancergen.2017.03.001. Epub 2017 Mar 16.

PMID:
28595733
9.

Metastatic intestinal adenocarcinoma to a lymph node involved by follicular lymphoma: The importance of looking beyond the apparent.

Acosta AM, Sonawane S, Sharif A, Pins MR.

Pathol Res Pract. 2017 Jun;213(6):713-716. doi: 10.1016/j.prp.2016.12.002. Epub 2016 Dec 5.

PMID:
28476376
10.

Poorly Differentiated Esophageal Adenocarcinoma Metastatic to a Well-differentiated Lung Adenocarcinoma: When Morphology and Immunohistochemistry Prevail Over Molecular Results.

Acosta AM, Wakeman K, Haroon Al Rasheed MR, Pins MR.

Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):e58-e60. doi: 10.1097/PAI.0000000000000419. No abstract available.

PMID:
27438516
11.

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS.

Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9. Erratum in: Lancet. 2016 May 14;387(10032):1998.

12.
13.
14.

Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.

Dutta S, Bandyopadhyay C, Bottero V, Veettil MV, Wilson L, Pins MR, Johnson KE, Warshall C, Chandran B.

Mol Oncol. 2014 May;8(3):483-507. doi: 10.1016/j.molonc.2013.12.017. Epub 2014 Jan 4.

15.

Small-intestine pneumocystis jiroveci pseudotumor as an acquired immunodeficiency syndrome-presenting illness: report of a case and review of the literature.

Zhou Y, Shetty J, Pins MR.

Arch Pathol Lab Med. 2012 Sep;136(9):1001-3. doi: 10.5858/arpa.2011-0221-CR. Review.

PMID:
22938587
16.

Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer.

Jabbari S, Pins M, Kruczek K, Nabhan C.

Avicenna J Med. 2011 Oct;1(2):52-4. doi: 10.4103/2231-0770.90916.

17.

Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.

Liu G, Chen YH, Kolesar J, Huang W, Dipaola R, Pins M, Carducci M, Stein M, Bubley GJ, Wilding G.

Urol Oncol. 2013 Feb;31(2):211-8. doi: 10.1016/j.urolonc.2011.01.002. Epub 2011 Jul 23.

18.

A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.

Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J.

Med Oncol. 2012 Jun;29(2):761-7. doi: 10.1007/s12032-011-9829-8. Epub 2011 Feb 6.

19.

Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198.

Wolff AC, Wang M, Li H, Pins MR, Pretorius FJ, Rowland KM, Sparano JA, Davidson NE.

Breast Cancer Res Treat. 2010 May;121(1):111-20. doi: 10.1007/s10549-010-0838-7. Epub 2010 Mar 24.

20.

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.

Moulder S, Li H, Wang M, Gradishar WJ, Perez EA, Sparano JA, Pins M, Yang X, Sledge GW.

Breast Cancer Res Treat. 2010 Feb;119(3):663-71. doi: 10.1007/s10549-009-0658-9.

21.

Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.

Argiris A, Buchanan A, Brockstein B, Kolesar J, Ghebremichael M, Pins M, Hahn K, Axelrod R, Forastiere A.

Cancer. 2009 Oct 1;115(19):4504-13. doi: 10.1002/cncr.24528.

22.

Suppressive roles of calreticulin in prostate cancer growth and metastasis.

Alur M, Nguyen MM, Eggener SE, Jiang F, Dadras SS, Stern J, Kimm S, Roehl K, Kozlowski J, Pins M, Michalak M, Dhir R, Wang Z.

Am J Pathol. 2009 Aug;175(2):882-90. doi: 10.2353/ajpath.2009.080417. Epub 2009 Jul 16.

23.

Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.

Zhang Q, Helfand BT, Jang TL, Zhu LJ, Chen L, Yang XJ, Kozlowski J, Smith N, Kundu SD, Yang G, Raji AA, Javonovic B, Pins M, Lindholm P, Guo Y, Catalona WJ, Lee C.

Clin Cancer Res. 2009 May 15;15(10):3557-67. doi: 10.1158/1078-0432.CCR-08-1656. Epub 2009 May 15.

24.

Recommendations for collection and handling of specimens from group breast cancer clinical trials.

Leyland-Jones BR, Ambrosone CB, Bartlett J, Ellis MJ, Enos RA, Raji A, Pins MR, Zujewski JA, Hewitt SM, Forbes JF, Abramovitz M, Braga S, Cardoso F, Harbeck N, Denkert C, Jewell SD; Breast International Group; Cooperative Groups of the Breast Cancer Intergroup of North America (TBCI); American College of Surgeons Oncology Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; National Cancer Institute of Canada Clinical Trials Group; Southwest Oncology Group; National Surgical Adjuvant Breast and Bowel Project; Radiation Oncology Group; Gynecologic Oncology Group; Children's Oncology Group.

J Clin Oncol. 2008 Dec 1;26(34):5638-44. doi: 10.1200/JCO.2007.15.1712. Epub 2008 Oct 27.

25.

A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.

Arteaga CL, O'Neill A, Moulder SL, Pins M, Sparano JA, Sledge GW, Davidson NE.

Clin Cancer Res. 2008 Oct 1;14(19):6277-83. doi: 10.1158/1078-0432.CCR-08-0482.

26.

Tissue-based research in kidney cancer: current challenges and future directions.

Signoretti S, Bratslavsky G, Waldman FM, Reuter VE, Haaga J, Merino M, Thomas GV, Pins MR, Libermann T, Gillespie J, Tomaszewski JE, Compton CC, Hruszkewycz A, Linehan WM, Atkins MB.

Clin Cancer Res. 2008 Jun 15;14(12):3699-705. doi: 10.1158/1078-0432.CCR-07-4733. Review.

27.

Pathologic outcomes during the learning curve for robotic-assisted laparoscopic radical prostatectomy.

Shah A, Okotie OT, Zhao L, Pins MR, Bhalani V, Dalton DP.

Int Braz J Urol. 2008 Mar-Apr;34(2):159-62; discussion 163.

28.

The methodology used to measure differential gene expression affects the outcome.

Ding Y, Xu L, Jovanovic BD, Helenowski IB, Kelly DL, Catalona WJ, Yang XJ, Pins M, Bergan RC.

J Biomol Tech. 2007 Dec;18(5):321-30.

29.

U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia.

Xiao W, Zhang Q, Habermacher G, Yang X, Zhang AY, Cai X, Hahn J, Liu J, Pins M, Doglio L, Dhir R, Gingrich J, Wang Z.

Oncogene. 2008 Mar 6;27(11):1536-44. Epub 2007 Sep 17.

30.

Expression and function of the human androgen-responsive gene ADI1 in prostate cancer.

Oram SW, Ai J, Pagani GM, Hitchens MR, Stern JA, Eggener S, Pins M, Xiao W, Cai X, Haleem R, Jiang F, Pochapsky TC, Hedstrom L, Wang Z.

Neoplasia. 2007 Aug;9(8):643-51.

31.

Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.

Argiris A, Hensing T, Yeldandi A, Patel S, Raji A, Sturgis C, Masters G, Gooding W, Pins M, Kolesar J.

J Thorac Oncol. 2006 Jan;1(1):52-60.

32.
33.

Juxtaglomerular apparatus tumor: a rare, surgically correctable cause of hypertension.

Rubenstein JN, Eggener SE, Pins MR, Rosner K, Chugh S, Campbell SC.

Rev Urol. 2002 Fall;4(4):192-5.

34.

Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle.

Zhang Q, Yang XJ, Kundu SD, Pins M, Javonovic B, Meyer R, Kim SJ, Greenberg NM, Kuzel T, Meagher R, Guo Y, Lee C.

Mol Cancer Ther. 2006 Jul;5(7):1733-43.

35.

The leader sequence triggers and enhances several functions of clusterin and is instrumental in the progression of human prostate cancer in vivo and in vitro.

Zhang Q, Zhou W, Kundu S, Jang TL, Yang X, Pins M, Smith N, Jovanovic B, Xin D, Liang L, Guo Y, Lee C.

BJU Int. 2006 Aug;98(2):452-60.

36.

Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification.

Ding Y, Xu L, Chen S, Jovanovic BD, Helenowski IB, Kelly DL, Catalona WJ, Yang XJ, Pins M, Ananthanarayanan V, Bergan RC.

Prostate Cancer Prostatic Dis. 2006;9(4):379-91. Epub 2006 Jun 20.

PMID:
16786039
37.

A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.

Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, Wong S, Lu Y, Pins M, Dancey J, Vokes E.

Cancer Biol Ther. 2006 Jul;5(7):766-70. Epub 2006 Jul 2.

PMID:
16760642
38.

Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.

Eklund J, Kozloff M, Vlamakis J, Starr A, Mariott M, Gallot L, Jovanovic B, Schilder L, Robin E, Pins M, Bergan RC.

Cancer. 2006 Jun 1;106(11):2459-65.

39.

Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer.

Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, Gann PH.

BMC Cancer. 2006 Mar 17;6:73.

40.

Tumor necrosis factor promotes differential trafficking of bladder mast cells in neurogenic cystitis.

Chen MC, Blunt LW, Pins MR, Klumpp DJ.

J Urol. 2006 Feb;175(2):754-9.

PMID:
16407045
41.

Mixed epithelial and stromal tumor of the kidney and cystic nephroma share overlapping features: reappraisal of 15 lesions.

Antic T, Perry KT, Harrison K, Zaytsev P, Pins M, Campbell SC, Picken MM.

Arch Pathol Lab Med. 2006 Jan;130(1):80-5.

PMID:
16390243
42.

Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.

Zhang Q, Jang TL, Yang X, Park I, Meyer RE, Kundu S, Pins M, Javonovic B, Kuzel T, Kim SJ, Van Parijs L, Smith N, Wong L, Greenberg NM, Guo Y, Lee C.

Prostate. 2006 Feb 15;66(3):235-47.

PMID:
16173028
43.

Mammary serine protease inhibitor (Maspin) binds directly to interferon regulatory factor 6: identification of a novel serpin partnership.

Bailey CM, Khalkhali-Ellis Z, Kondo S, Margaryan NV, Seftor RE, Wheaton WW, Amir S, Pins MR, Schutte BC, Hendrix MJ.

J Biol Chem. 2005 Oct 7;280(40):34210-7. Epub 2005 Jul 26.

44.

A molecular classification of papillary renal cell carcinoma.

Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, Kort EJ, Futami K, Furge KA, Takahashi M, Kanayama HO, Tan PH, Teh BS, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang NG, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT.

Cancer Res. 2005 Jul 1;65(13):5628-37.

45.

Insensitivity to transforming growth factor-beta results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP).

Zhang Q, Rubenstein JN, Jang TL, Pins M, Javonovic B, Yang X, Kim SJ, Park I, Lee C.

Mol Endocrinol. 2005 Sep;19(9):2390-9. Epub 2005 May 19.

PMID:
15905358
46.

Renal medullary carcinoma and ABL gene amplification.

Simpson L, He X, Pins M, Huang X, Campbell SC, Yang XJ, Perlman EJ, Bergan RC.

J Urol. 2005 Jun;173(6):1883-8.

PMID:
15879768
47.

Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.

Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg NM, Liu V, Guo Y, Lee C.

Cancer Res. 2005 Mar 1;65(5):1761-9.

48.

Immunohistochemical assays in prostatic biopsies processed in Bouin's fixative.

Ananthanarayanan V, Pins MR, Meyer RE, Gann PH.

J Clin Pathol. 2005 Mar;58(3):322-4.

49.

Histopathology of human renal tumors after laparoscopic renal cryosurgery.

Jang TL, Wang R, Kim SC, Troe T, Pins MR, Nadler RB.

J Urol. 2005 Mar;173(3):720-4.

PMID:
15711251

Supplemental Content

Support Center